June 18, 2012
/PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:
), a leading provider of biopharmaceutical products in
, today announced that management is scheduled to present at the 5th Annual BioPharma China Convention 2012, to be held
and 21 at the Beijing Marriot Hotel Northeast in
, China. Bringing together more than 300 global biopharmaceutical professionals, the 2012 convention will focus on opportunities for greater achievements in novel vaccines and monoclonal antibody (mAb) drugs.
, Sinovac's Director of International Business Development & Investor Relations, will deliver a presentation entitled, "Keeping Abreast with Global Vaccine Frontiers & Providing High Quality Vaccines to the World", on
June 21, 2012
Ms. Yang participated at the 3rd International Roundtable on China-Africa Health Collaboration on
June 12, 2012
. The conference, organized by the Institute for Global Health, Peking University, bought together the Chinese Ministry of Commerce, the Chinese Ministry of Health, international health organizations, and African officials to strengthen communication, and discuss issues and solutions related to collaboration, between the two countries. Ms. Yang delivered a presentation entitled, "Environmental Prerequisites to Investing in the Pharmaceutical Sector in Developing Countries", that aimed to raise Sinovac's profile across the international healthcare industry, attract potential partners for international markets, and showcase its international strategy to key government and partnering constituencies.
Sinovac Biotech Ltd. is a
-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu) and H1N1 influenza (swine flu), as well as animal rabies vaccine for canines. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for Enterovirus71 (against hand, foot and mouth disease), pneumococcal conjugate, pneumococcal polysaccharides, mumps and rubella. Sinovac sells its vaccines mainly in
and exports selected vaccines to
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.